Innate Pharma SA (IPHA) stock
Close on Nov 11, 2026Market cap $149.01MP/E –Yield –
Innate Pharma SA saw revenue fall 55.2% to €9.01M over fiscal 2025. Free cash flow was -€52.90M. At the latest close the market valued the company at €133.60M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- €133.60M
- P/E ratio
- –
- Price to sales
- 14.84
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -39.59%
Fundamentals
- Revenue
- €9.01M
- EPS, diluted
- -0.55 EUR
- Free cash flow
- -€52.90M
Trading
- Previous close
- $1.54
- Open
- $1.54
- Day's range
- $1.53 – $1.61
- Volume
- 7,572
- Average volume (20 days)
- 16,580
- Beta (5 years)
- 0.95
- RSI (14 days)
- 55.0
- Volatility (1 year)
- 94.9%
- Relative volume
- 0.06×
- WACC
- 9.6%
Market cap history
Month-end market cap since 2019, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | IPHA | S&P 500 | Difference | IPHA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.9% | -2.4% | +0.6 pts | ||
| 3 months | -26.0% | -1.2% | −24.9 pts | ||
| Year to date | -9.1% | +12.3% | −21.4 pts | ||
| 1 year | -25.7% | +12.4% | −38.1 pts | ||
| 3 years | -32.9% | +78.8% | −111.7 pts | -12.5% | +21.4% |
| 5 years | -70.3% | +75.2% | −145.4 pts | -21.5% | +11.9% |
Ten years at a glance
Fiscal years 2016 to 2025, EUR
Revenue
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Innate Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Innate Pharma
Biological Products, (No Diagnostic Substances)
Innate Pharma S.A. is a clinical-stage biotechnology company that develops immunotherapies for cancer patients. The company utilizes antibody-engineering expertise to create next-generation antibody therapeutics, focusing on oncology indications with high unmet medical needs. Its clinical drug pipeline includes lacutamab, an antibody targeting KIR3DL2 for T-cell lymphomas; IPH4502, an antibody-drug conjugate directed against Nectin-4 for solid tumors; and monalizumab, an immune checkpoint inhibitor targeting NKG2A. Innate collaborates with major biopharmaceutical companies, such as AstraZeneca and Sanofi, as well as academic and research institutions, which act as development partners and commercial collaborators.
Company profile, executives and historyInnate Pharma stock: common questions
What is Innate Pharma's stock price?
IPHA closed at $1.59 on Nov 11, 2026, up 3.25% on the day.
What is Innate Pharma's market cap?
Innate Pharma was worth $149.01M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is IPHA's P/E ratio?
Innate Pharma lost money over fiscal 2025 (diluted EPS -0.55 EUR), so it has no meaningful P/E ratio.
How much revenue does Innate Pharma make?
Innate Pharma reported revenue of €9.01M for fiscal 2025, down 55.2% from a year earlier.
Does Innate Pharma pay a dividend?
No. Innate Pharma has not paid a cash dividend over the last twelve months.
How has IPHA stock performed over the past year?
Including dividends, IPHA returned -25.7% over the past year, against +12.4% for the S&P 500.
Who are Innate Pharma's competitors?
Companies most similar to Innate Pharma by business, industry and size include MOLN, TCRX, EVAX, ATRA, CRBU.
See a number that looks wrong?